

レジメン名 MEC療法(寛解導入) 対象疾患 急性骨髄性白血病

| ChemoNavi | | 治療内容 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|--|--|----------|---------------------------------------|--|-------|---|---|--------------------|-------------------|---------------------|------------------|--------------------|--------|--|---------|--------------------|---------------|-----|--|------------------------|-----|----------|--|---|--|---------|----|-------|--------|--------------------|---|---|--|---------|----|---------|--------|--------------------|---|---|--|---------|--------|--------------------------|---|---|---|----------|----|--|----------|--|--|--|----------|--|
| <table border="1"> <thead> <tr> <th>薬品名(成分名)</th> <th>投与量</th> <th>投与日</th> </tr> </thead> <tbody> <tr> <td>エトボシド</td> <td>80mg/m²</td> <td>day1-6</td> </tr> <tr> <td>シタラビン</td> <td>1g/m²</td> <td>day1-6</td> </tr> <tr> <td>ノバントロン(ミトキサントロン)</td> <td>6mg/m²</td> <td>day1-6</td> </tr> </tbody> </table> | | 薬品名(成分名) | 投与量 | 投与日 | エトボシド | 80mg/m ² | day1-6 | シタラビン | 1g/m ² | day1-6 | ノバントロン(ミトキサントロン) | 6mg/m ² | day1-6 | <table border="1"> <tr> <td>投与サイクル数</td> <td>2サイクルまで</td> </tr> </table> | 投与サイクル数 | 2サイクルまで | <p>day1-6</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 薬品名(成分名) | 投与量 | 投与日 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| エトボシド | 80mg/m ² | day1-6 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| シタラビン | 1g/m ² | day1-6 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| ノバントロン(ミトキサントロン) | 6mg/m ² | day1-6 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 投与サイクル数 | 2サイクルまで | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <table border="1"> <tr> <td>総投与時間</td> <td>day1:14時間 day2-6:24時間 day7:10時間</td> </tr> </table> | | 総投与時間 | day1:14時間 day2-6:24時間 day7:10時間 | <div style="border: 1px solid black; padding: 5px;"> <p>※別ルートから点滴</p> <table border="1"> <tr> <td>② 生理食塩液</td> <td>100 ml</td> </tr> <tr> <td colspan="2">10:00 ルート確保・フラッシュ用</td> </tr> <tr> <td colspan="2" style="text-align: center;">↓</td> </tr> <tr> <td>③ ソルコーテフ</td> <td>100 mg</td> </tr> <tr> <td>生理食塩液</td> <td>50 ml</td> </tr> <tr> <td colspan="2">10:00-10:15 点滴、15分</td> </tr> <tr> <td colspan="2" style="text-align: center;">↓</td> </tr> <tr> <td>④ グラニセトロンバック(3mg/50mL)</td> <td>1 袋</td> </tr> <tr> <td colspan="2">10:15 全開</td> </tr> <tr> <td colspan="2" style="text-align: center;">↓</td> </tr> <tr> <td>⑤ エトボシド</td> <td>mg</td> </tr> <tr> <td>生理食塩液</td> <td>500 ml</td> </tr> <tr> <td colspan="2">10:25-11:25 点滴、1時間</td> </tr> <tr> <td colspan="2" style="text-align: center;">↓</td> </tr> <tr> <td>⑥ シタラビン</td> <td>mg</td> </tr> <tr> <td>5%ブドウ糖液</td> <td>400 ml</td> </tr> <tr> <td colspan="2">11:25-17:25 点滴、6時間</td> </tr> <tr> <td colspan="2" style="text-align: center;">↓</td> </tr> <tr> <td>⑦ 生理食塩液</td> <td>250 ml</td> </tr> <tr> <td colspan="2">17:25-20:25 経過観察用 点滴、3時間</td> </tr> <tr> <td colspan="2" style="text-align: center;">↓</td> </tr> <tr> <td>⑧ ノバントロン</td> <td>mg</td> </tr> <tr> <td>生理食塩液</td> <td>100 ml</td> </tr> <tr> <td colspan="2">20:25-20:55 点滴、30分</td> </tr> </table> </div> | | ② 生理食塩液 | 100 ml | 10:00 ルート確保・フラッシュ用 | | ↓ | | ③ ソルコーテフ | 100 mg | 生理食塩液 | 50 ml | 10:00-10:15 点滴、15分 | | ↓ | | ④ グラニセトロンバック(3mg/50mL) | 1 袋 | 10:15 全開 | | ↓ | | ⑤ エトボシド | mg | 生理食塩液 | 500 ml | 10:25-11:25 点滴、1時間 | | ↓ | | ⑥ シタラビン | mg | 5%ブドウ糖液 | 400 ml | 11:25-17:25 点滴、6時間 | | ↓ | | ⑦ 生理食塩液 | 250 ml | 17:25-20:25 経過観察用 点滴、3時間 | | ↓ | | ⑧ ノバントロン | mg | 生理食塩液 | 100 ml | 20:25-20:55 点滴、30分 | | | | |
| 総投与時間 | day1:14時間 day2-6:24時間 day7:10時間 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| ② 生理食塩液 | 100 ml | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 10:00 ルート確保・フラッシュ用 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| ↓ | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| ③ ソルコーテフ | 100 mg | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 生理食塩液 | 50 ml | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 10:00-10:15 点滴、15分 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| ↓ | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| ④ グラニセトロンバック(3mg/50mL) | 1 袋 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 10:15 全開 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| ↓ | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| ⑤ エトボシド | mg | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 生理食塩液 | 500 ml | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 10:25-11:25 点滴、1時間 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| ↓ | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| ⑥ シタラビン | mg | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 5%ブドウ糖液 | 400 ml | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 11:25-17:25 点滴、6時間 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| ↓ | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| ⑦ 生理食塩液 | 250 ml | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 17:25-20:25 経過観察用 点滴、3時間 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| ↓ | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| ⑧ ノバントロン | mg | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 生理食塩液 | 100 ml | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 20:25-20:55 点滴、30分 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <table border="1"> <tr> <td>① ソリタT1</td> <td>500 ml</td> </tr> <tr> <td colspan="2">10:00-22:00 点滴、12時間</td> </tr> </table> | | ① ソリタT1 | 500 ml | 10:00-22:00 点滴、12時間 | | <table border="1"> <tr> <td>⑨ ソリタT1</td> <td>500 ml</td> </tr> <tr> <td colspan="2">22:00-10:00 点滴、12時間</td> </tr> </table> | | ⑨ ソリタT1 | 500 ml | 22:00-10:00 点滴、12時間 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| ① ソリタT1 | 500 ml | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 10:00-22:00 点滴、12時間 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| ⑨ ソリタT1 | 500 ml | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 22:00-10:00 点滴、12時間 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <table border="1"> <tr> <th>投与スケジュール</th> <th>1</th> <th>2</th> <th>3</th> <th>4</th> <th>5</th> <th>6</th> <th>.....</th> </tr> <tr> <td>MEC療法(寛解導入)</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>治療日</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>エトボシド</td> <td>●</td> <td>●</td> <td>●</td> <td>●</td> <td>●</td> <td>●</td> <td></td> </tr> <tr> <td>シタラビン</td> <td>●</td> <td>●</td> <td>●</td> <td>●</td> <td>●</td> <td>●</td> <td></td> </tr> <tr> <td>ノバントロン</td> <td>●</td> <td>●</td> <td>●</td> <td>●</td> <td>●</td> <td>●</td> <td></td> </tr> </table> | | 投与スケジュール | 1 | 2 | 3 | 4 | 5 | 6 | | MEC療法(寛解導入) | | | | | | | | 治療日 | | | | | | | | エトボシド | ● | ● | ● | ● | ● | ● | | シタラビン | ● | ● | ● | ● | ● | ● | | ノバントロン | ● | ● | ● | ● | ● | ● | | <table border="1"> <tr> <td>血管外漏出リスク</td> <td>エトボシド: 炎症性抗がん剤 シタラビン: 非壊死性抗がん剤 ノバントロン(ミトキサントロン): 壊死性抗がん剤</td> </tr> </table> | 血管外漏出リスク | エトボシド: 炎症性抗がん剤 シタラビン: 非壊死性抗がん剤 ノバントロン(ミトキサントロン): 壊死性抗がん剤 | <table border="1"> <tr> <td>その他の必要薬剤</td> <td></td> </tr> </table> | | その他の必要薬剤 | |
| 投与スケジュール | 1 | 2 | 3 | 4 | 5 | 6 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| MEC療法(寛解導入) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 治療日 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| エトボシド | ● | ● | ● | ● | ● | ● | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| シタラビン | ● | ● | ● | ● | ● | ● | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| ノバントロン | ● | ● | ● | ● | ● | ● | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 血管外漏出リスク | エトボシド: 炎症性抗がん剤 シタラビン: 非壊死性抗がん剤 ノバントロン(ミトキサントロン): 壊死性抗がん剤 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| その他の必要薬剤 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <table border="1"> <tr> <td>投与時の注意事項</td> <td>・Rp.1とRp.2はそれぞれ別々のルートから同時に点滴始める。</td> </tr> </table> | | 投与時の注意事項 | ・Rp.1とRp.2はそれぞれ別々のルートから同時に点滴始める。 | <table border="1"> <tr> <td>備考欄</td> <td>シタラビン症候群(結膜炎)予防のため、フルメトロン点眼はday1~day10投与する。</td> </tr> </table> | | 備考欄 | シタラビン症候群(結膜炎)予防のため、フルメトロン点眼はday1~day10投与する。 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 投与時の注意事項 | ・Rp.1とRp.2はそれぞれ別々のルートから同時に点滴始める。 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 備考欄 | シタラビン症候群(結膜炎)予防のため、フルメトロン点眼はday1~day10投与する。 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |